{"nctId":"NCT00430950","briefTitle":"Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","startDateStruct":{"date":"2007-02"},"conditions":["Essential Hypertension"],"count":1011,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg"]}],"interventions":[{"name":"olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets","otherNames":[]},{"name":"olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female Europeans aged 18 years or older with moderate to severe HTN, defined as follows (conventional BP measurements)\n\nExclusion Criteria:\n\n* Female patients of childbearing potential pregnant, lactating or planning to become pregnant during the trial period.\n* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the study medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.\n* Patients having a history of the following within the last six months:\n\n  * myocardial infarction,\n  * unstable angina pectoris,\n  * percutaneous coronary intervention,\n  * severe heart failure,\n  * hypertensive encephalopathy, cerebrovascular accident (stroke) or\n  * transient ischaemic attack.\n* Patients with clinically significant abnormal laboratory values at screening.\n* Patients with secondary HTN.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Trough Sitting Diastolic Blood Pressure","description":"Change in mean trough sitting diastolic Blood Pressure between OM/HCTZ 20/25 mg vs. 40/25 mg, in those patients inadequately controlled on OM 40 mg monotherapy, after eight weeks of double blind treatment, as compared to baseline.\n\nChange = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.16","spread":"8.851"},{"groupId":"OG001","value":"-10.45","spread":"7.928"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12","description":"Change = Week 12 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.32","spread":"7.820"},{"groupId":"OG001","value":"-8.83","spread":"7.584"}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Systolic Blood Pressure 4 Weeks and 8 Weeks After Baseline.","description":"4 weeks Change = Week 12 - Week 8 (baseline). 8 weeks Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.41","spread":"13.930"},{"groupId":"OG001","value":"-17.09","spread":"13.126"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.07","spread":"12.654"},{"groupId":"OG001","value":"-13.80","spread":"12.519"}]}]}]},{"type":"SECONDARY","title":"Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"8.69"},{"groupId":"OG001","value":"-7.6","spread":"8.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"9.18"},{"groupId":"OG001","value":"-7.7","spread":"8.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"9.52"},{"groupId":"OG001","value":"-7.0","spread":"9.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.7","spread":"13.75"},{"groupId":"OG001","value":"-12.0","spread":"11.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"14.36"},{"groupId":"OG001","value":"-12.3","spread":"12.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"14.59"},{"groupId":"OG001","value":"-10.7","spread":"13.16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Blood Pressure Goal.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"260","spread":null},{"groupId":"OG001","value":"255","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}